Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Acquired Diseases
  • Published:

Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status

Abstract

Intraperitoneal (i.p.) recurrence of cisplatin-refractory and p53 mutant ovarian cancer is a major clinical problem, despite surgery and chemotherapy. dl1520 (ONYX-015) is an E1B–55 kDa gene-deleted adenovirus engineered selectively to replicate in and destroy cancer cells lacking functional p53. However, a correlation between efficacy and p53 function has not been definitively studied in vivo to date, and efficacy following i.p. administration had not been previously described. We therefore carried out experiments to address these issues in three nude mouse–human ovarian carcinomatosis xenograft models. Intraperitoneal treatment with dl1520 led to complete tumor eradication and/or significantly improved survival in two p53(−) nude mouse–human ovarian tumor xenograft models. OVCAR3 i.p. xenografts underwent complete regressions in 11 of 12 mice (versus one of seven controls; P = 0.001), while mice bearing cisplatin-resistant A2780 tumors had significantly improved survival versus controls (P = 0.05). In contrast, the A2780 p53(+) ovarian cancer xenograft was resistant to dl1520. The efficacy of i.p. dl1520 in the p53(−) models correlated strongly with tumor burden present at the time of treatment initiation, and no efficacy was seen with non-replicating/UV-inactivated dl1520. Selectively replicating viruses such as dl1520 hold promise as i.p. therapies for p53-deficient and chemotherapy-resistant ovarian carcinomas. A phase I clinical trial of i.p. dl1520 (ONYX-015) is underway in patients with cisplatin-resistant ovarian carcinoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Young RC Jr et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials New Engl J Med 1990 322: 1021–1027

    Article  PubMed  Google Scholar 

  2. McGuire WP et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer New Engl J Med 1996 334: 1–6

    Article  CAS  PubMed  Google Scholar 

  3. Alberts DS et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer New Engl J Med 1996 335: 1950–1955

    Article  CAS  PubMed  Google Scholar 

  4. Kaye SB . Ovarian cancer, from the laboratory to the clinic: challenges for the future Ann Oncol 1996 7: 9–13

    Article  CAS  PubMed  Google Scholar 

  5. Zheng J et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas J Natl Cancer Inst 1995 87: 1146–1153

    Article  CAS  PubMed  Google Scholar 

  6. Righetti SC et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res 1996 56: 689–693

    CAS  PubMed  Google Scholar 

  7. Perego P et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res 1996 56: 556–562

    CAS  PubMed  Google Scholar 

  8. Eliopoulos AG et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2 Oncogene 1995 11: 1217–1228

    CAS  PubMed  Google Scholar 

  9. Yaginuma Y, Westphal H . Abnormal structure and function of the p53 gene in human ovarian carcinoma cell lines Cancer Res 1992 52: 4196–4199

    CAS  PubMed  Google Scholar 

  10. Chang F, Syrjanen S, Syrjanen K . Implications of the p53 tumor-suppressor gene in clinical oncology J Clin Oncol 1995 13: 1009–1022

    Article  CAS  PubMed  Google Scholar 

  11. Anthoney DA et al. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells Cancer Res 1996 56: 1374–1381

    CAS  PubMed  Google Scholar 

  12. Behrens BC et al. Characterization of a cis-diammine dichloroplatinum resistant human ovarian cell line and its use in evaluation of platinum analogues Cancer Res 1987 47: 414–418

    CAS  PubMed  Google Scholar 

  13. Braun et al. Increased accumulation of p53 in cisplatin-resistant ovarian cells Int J Cancer 1993 55: 678–684

    Article  Google Scholar 

  14. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  15. Rogulski KR et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy Cancer Res 2000 60: 1193–1196

    CAS  PubMed  Google Scholar 

  16. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nature Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  17. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW . p53-dependent cell death/apoptosis is required for a productive adenovirus infection Nature Med 1998 4: 1068–1072

    Article  CAS  PubMed  Google Scholar 

  18. Harada J, Berk A . p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication J Virol 1999 73: 5333–5344

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Goodrum FD, Ornelles DA . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 1998 72: 9479–9490

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Scheffner M et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell 1990 63: 1129–1136

    Article  CAS  PubMed  Google Scholar 

  21. Leach FS et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas Cancer Res 1993 53: 2231–2234

    CAS  PubMed  Google Scholar 

  22. Ganly I et al. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806

    CAS  PubMed  Google Scholar 

  23. Kirn D et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer Proc Am Soc Clin Oncol 1998 17: 391 (Abstr.)

    Google Scholar 

  24. Khuri F et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer Nature Med 2000 6: 879–885

    Article  CAS  PubMed  Google Scholar 

  25. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121

    Article  CAS  PubMed  Google Scholar 

  26. Heise C et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628

    CAS  PubMed  Google Scholar 

  27. Heise C, Williams A, Olesch J, Kirn DH . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects Cancer Gene Ther 1999 6: 499–504

    Article  CAS  PubMed  Google Scholar 

  28. Mujoo K, Maneval D, Anderson S, Gutterman J . Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma Oncogene 1996 12: 1617–1623

    CAS  PubMed  Google Scholar 

  29. Munshi A, Ramesh R, Marrogi A, Freeman S . Evaluation of adenovirus p53-mediated ‘bystander effect’ in vivo Cancer Gene Ther 1997 4: S13 (Abstr.)

    Google Scholar 

  30. Freeman SM et al. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells Cancer Lett 1995 92: 167–174

    Article  CAS  PubMed  Google Scholar 

  31. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nature Med 1995 1: 938–943

    Article  CAS  PubMed  Google Scholar 

  32. Coukos G et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer Clin Cancer Res 1999 5: 1523–1537

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Ynez Dugen and Olga Diri for technical assistance with this manuscript; Suzette Weber for animal study work; Prof Stan Kaye and Patrick Trown for many insightful discussions.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heise, C., Ganly, I., Kim, Y. et al. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 7, 1925–1929 (2000). https://doi.org/10.1038/sj.gt.3301319

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301319

Keywords

This article is cited by

Search

Quick links